Skip to content
NBDC Human Database

No datasets in the cart.

Go to the cart

Due to system maintenance, the application system, application review by the Data Access Committee will be unavailable during the following period.
Schedule: October 5th (Mon), 2026, 9:00 - October 7th (Wed), 2026, 15:00 (JST)
We apologize for any inconvenience this may cause and appreciate your understanding.

We are currently receiving a large number of applications for data submission, and the review process is taking longer than usual.We sincerely apologize for the delay and kindly ask for your understanding. When submitting an application, we would greatly appreciate it if you could allow sufficient time for the processing.

Following a change to our organizational structure effective April 1, 2026, this division has been renamed from the "Database Center for Life Science, Joint Support-Center for Data Science Research" to the "Database Division for Life Science (DBCLS), BioData Science Initiative (BSI), National Institute of Genetics (NIG)". Where the former name still appears in the guidelines, please read it as the new name.

Dataset ID

JGAD000674

Type of data
NGS (Target Capture, WGS, scRNA-seq, scATAC-seq, ChIP-seq)
Access criteria
Controlled-access (Type I)
Total data volume
4.7 TB
File formats
  • FASTQ
Research
hum0252
Date published
2023-12-06
Date modified
2025-12-09
DDBJ Search
JGAD000674 (opens in a new tab)
JGA Study
JGAS000553 (opens in a new tab)

Analysis method

Targeted DNA sequencing

Materials and participants
ATL (ICD10: C915): 4 + 6 cases (total 30 + 23 samples)
non-tumor cells: 4 + 11 samples
tumor cells: before valemetostat treatment: 4 + 6 samples, after valemetostat treatment: 22 + 6 samples
  • Health status
    Affected
  • Subject count
    10 (Individual)
Disease
ATL (C915)
Sample description
DNAs extracted from infected cells, uninfected cells, non-tumor and tumor cells of ATL and HTLV-1 carriers
  • Tissue
    Peripheral blood
  • Tumor / normal
    Mixed
Sample provider
N/A
Experimental method
Targeted DNA sequencing
Target
280 genes including 50 candidate genes for ATL
Reagent kit
SureSelect Target Enrichment System
Fragmentation
Ultrasonic fragmentation (Covaris)
Platform
Illumina HiSeq 2500
Illumina HiSeq 3000
Illumina NovaSeq 6000
Read type
Paired-end
Read length
JGAD000412, JGAD000674: 200 bp
JGAD000674 (additional): 100 bp
Data use policy
NBDC data sharing policy (JGAP000001)

scRNA-seq

Materials and participants
ATL (ICD10: C915): 3 + 3 cases (total 10 + 11 samples)
peripheral blood lymphocytes: before valemetostat treatment: 3 + 7 samples, after valemetostat treatment: 7 + 4 samples
  • Health status
    Affected
  • Subject count
    6 (Individual)
Disease
ATL (C915)
Sample description
RNAs extracted from single CD4+ T cells with/without infection of ATL or peripheral blood lymphocytes of ATL cases before and after valemetostat treatment
  • Tissue
    Peripheral blood
  • Tumor / normal
    Tumor
Sample provider
N/A
Experimental method
scRNA-seq
Target
N/A
Reagent kit
Chromium Single Cell 3' v2
Chromium Single Cell 5'
Fragmentation
included in the above library construction kit (enzymatic fragmentation)
Platform
Illumina HiSeq 2500
Illumina HiSeq 3000
Illumina NovaSeq 6000
Read type
Mixed
Read length
JGAD000412, JGAD000674: 124 bp
JGAD000674 (additional): 91–98 bp
Data use policy
NBDC data sharing policy (JGAP000001)

WGS

Materials and participants
ATL (ICD10: C915): 3 cases (total 9 samples)
non-tumor cells: 3 samples
tumor cells: before valemetostat treatment: 3 samples, after valemetostat treatment: 3 samples
  • Health status
    Affected
  • Subject count
    3 (Individual)
Disease
ATL (C915)
Sample description
DNAs extracted from normal cells and tumor cells
  • Tumor / normal
    Mixed
Sample provider
N/A
Experimental method
WGS
Target
N/A
Reagent kit
MGIEasy PCR-Free DNA Library Prep Set
Fragmentation
Ultrasonic fragmentation (Covaris)
Platform
MGI DNBSEQ-G400
Read type
Paired-end
Read length
300 bp
Data use policy
NBDC data sharing policy (JGAP000001)

scATAC-seq

Materials and participants
ATL (ICD10: C915): 3 + 3 cases (total 10 + 11 samples)
peripheral blood lymphocytes: before valemetostat treatment: 3 + 7 samples, after valemetostat treatment: 7 + 4 samples
  • Health status
    Affected
  • Subject count
    21 (Sample)
Disease
ATL (C915)
Sample description
DNAs extracted from peripheral blood lymphocytes of ATL cases before and after valemetostat treatment
  • Tissue
    Lymphocyte, Peripheral blood
Sample provider
N/A
Experimental method
scATAC-seq
Target
N/A
Reagent kit
Chromium Next GEM Single Cell ATAC v1.1
Fragmentation
enzymatic fragmentation
Platform
Illumina NovaSeq 6000
Read type
Paired-end
Read length
100 bp
JGAD000674 (additional): 49 bp (50×)
Data use policy
NBDC data sharing policy (JGAP000001)

ChIP-seq

Materials and participants
ATL (ICD10: C915): 1 + 2 case
CD4+ T cells from 1 cell line
  • Health status
    Mixed
  • Subject count
    4 (Individual)
Disease
ATL (C915)
Sample description
DNAs extracted from CD4+ T cells and tumor cells and immunoprecipitated with anti-histone antibodies (H3K27me3, H3K27ac)
ATL tumor cells before valemetostat treatment: control 1 + 2 sample, ChIP 2 + 2 samples
ATL tumor cells after valemetostat treatment: ChIP 2 + 4 samples
CD4+ T cells: control 1 sample, ChIP 2 samples
  • Tissue
    CD4+ T cell
  • Tumor / normal
    Mixed
Sample provider
Human Peripheral Blood CD4+ T cells (Lonza Catalog #: 2W-200)
Experimental method
ChIP-seq
Target
N/A
Fragmentation
Ultrasonic fragmentation (Covaris)
Platform
Illumina NextSeq 500
Read type
Single-end
Read length
75 bp
Data use policy
NBDC data sharing policy (JGAP000001)